Effect of β-1,6-Glucan Inhibitors on the Invasion Process of Candida albicans : Potential Mechanism of Their In Vivo Efficacy
ABSTRACT
β-1,6-Glucan is a fungus-specific cell wall component that is essential for the retention of many cell wall proteins. We recently reported the discovery of a small molecule inhibitor of β-1,6-glucan biosynthesis in yeasts. In the course of our study of its derivatives, we found a unique feature in their antifungal profile. D21-6076, one of these compounds, exhibited potent in vitro and in vivo antifungal activities against Candida glabrata . Interestingly, although it only weakly reduced the growth of Candida albicans in conventional media, it significantly prolonged the survival of mice infected by the pathogen. Biochemical evaluation of D21-6076 indicated that it inhibited β-1,6-glucan synthesis of C. albicans , leading the cell wall proteins, which play a critical role in its virulence, to be released from the cell. Correspondingly, adhesion of C. albicans cells to mammalian cells and their hyphal elongation were strongly reduced by the drug treatment. The results of the experiment using an in vitro model of vaginal candidiasis showed that D21-6076 strongly inhibited the invasion process of C. albicans without a significant reduction in its growth in the medium. These evidences suggested that D21-6076 probably exhibited in vivo efficacy against C. albicans by inhibiting its invasion process.
Top-30
Journals
|
1
2
|
|
|
Future Medicinal Chemistry
2 publications, 6.25%
|
|
|
Yeast
2 publications, 6.25%
|
|
|
Journal of Medicinal Chemistry
2 publications, 6.25%
|
|
|
Biological and Pharmaceutical Bulletin
1 publication, 3.13%
|
|
|
Current Fungal Infection Reports
1 publication, 3.13%
|
|
|
International Journal of Antimicrobial Agents
1 publication, 3.13%
|
|
|
Materials Chemistry and Physics
1 publication, 3.13%
|
|
|
PLoS ONE
1 publication, 3.13%
|
|
|
Biotechnology Advances
1 publication, 3.13%
|
|
|
Materials Science and Engineering C
1 publication, 3.13%
|
|
|
Bioorganic and Medicinal Chemistry Letters
1 publication, 3.13%
|
|
|
Tetrahedron
1 publication, 3.13%
|
|
|
Drug Discovery Today
1 publication, 3.13%
|
|
|
ChemMedChem
1 publication, 3.13%
|
|
|
ACS Infectious Diseases
1 publication, 3.13%
|
|
|
Expert Opinion on Drug Discovery
1 publication, 3.13%
|
|
|
Medical Mycology
1 publication, 3.13%
|
|
|
mBio
1 publication, 3.13%
|
|
|
Infection and Immunity
1 publication, 3.13%
|
|
|
Microbiology spectrum
1 publication, 3.13%
|
|
|
Proceedings of the National Academy of Sciences of the United States of America
1 publication, 3.13%
|
|
|
Mendeleev Communications
1 publication, 3.13%
|
|
|
Ekologiya Cheloveka (Human Ecology)
1 publication, 3.13%
|
|
|
1
2
|
Publishers
|
1
2
3
4
5
6
7
8
9
|
|
|
Elsevier
9 publications, 28.13%
|
|
|
Taylor & Francis
3 publications, 9.38%
|
|
|
Wiley
3 publications, 9.38%
|
|
|
American Chemical Society (ACS)
3 publications, 9.38%
|
|
|
American Society for Microbiology
3 publications, 9.38%
|
|
|
Pharmaceutical Society of Japan
1 publication, 3.13%
|
|
|
Springer Nature
1 publication, 3.13%
|
|
|
Public Library of Science (PLoS)
1 publication, 3.13%
|
|
|
Oxford University Press
1 publication, 3.13%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
1 publication, 3.13%
|
|
|
OOO Zhurnal "Mendeleevskie Soobshcheniya"
1 publication, 3.13%
|
|
|
Eco-Vector LLC
1 publication, 3.13%
|
|
|
1
2
3
4
5
6
7
8
9
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.